EGFR and non-small cell lung carcinoma: For example, HDACi have been found to inhibit EGFR expression in non-small cell lung cancer (NSCLC) [[26], [27], [28]], head and neck cancer [[29], [30], [31]], colorectal carcinoma [32], breast cancer [33], pancreatic adenocarcinoma [34] and glioblastoma [35].